Device-guided Breathing for Shortness of Breath in COPD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01286181|
Recruitment Status : Completed
First Posted : January 31, 2011
Last Update Posted : April 4, 2013
|Condition or disease||Intervention/treatment||Phase|
|COPD Dyspnea Hyperinflation||Behavioral: Twice daily practice of device-guided slow breathing.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Device-guided Slow Breathing in COPD Patients With Clinically Significant Dyspnea: Phase 2|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
|Experimental: Device-guided slow breathing||
Behavioral: Twice daily practice of device-guided slow breathing.
Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
- Determine effect of increased device-guided breathing on health-related quality of life measures. [ Time Frame: 8 weeks ]Pre and post device use measures of dyspnea, health-related quality of life, stress, adn self-efficacy for managing chronic disease will be obtained through self-administered questionnaires.
- Evaluate effect of device-guided slow breathing on daily physical activity. [ Time Frame: 8 weeks ]Evaluate the effect of a higher intensity of device-guided breathing (20 minutes twice daily for 8 weeks) on daily physical activity, as measured by a gold-standard activity monitor, before and after device use.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01286181
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Roberto Benzo, MD||Mayo Clinic|